The Efficacy of Intermittent Versus Daily Oral Iron Supplementation in Anaemic Pregnant Women.
NCT ID: NCT05278793
Last Updated: 2022-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
58 participants
INTERVENTIONAL
2022-01-07
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iron Metabolism Parameters At First Trimester and preGnancy outcomE
NCT03176147
Once Versus Twice Daily Iron Supplementation in Pregnant Women
NCT02839096
Iron Deficiency Anemia in Twin Pregnancies
NCT04975074
The Oral Iron on the Prevention of Iron Deficiency Anemia in Obese Pregnant
NCT04101461
Early Detection of Anaemia During the Maternity
NCT00827463
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Iron deficiency anaemia in pregnancy is common and the standard treatment is iron supplementation once or twice daily. But there is no evidence for the optimal dose of iron supplementation in pregnancy. In non-pregnant women intermittent oral iron supplementation on alternate days is proven to have a similar effect on haemoglobin levels as iron supplementation daily with less side effects. In pregnancy the need and absorption of iron is physiologically higher. Therefore the optimal dose may differ from non-pregnant women.
The adverse effects of iron supplementation, which are mainly gastrointestinal effects, seem to be related to the dose of iron supplementation. These effects often already exist physiologically in pregnancy and may increase with the use of iron supplementation. Therefore, a lower dose would be preferable in pregnancy if the effectiveness is similar.
In this study intermittent dosage of iron supplementation three times a week will be compared to daily dosage in anaemic pregnant women due to iron deficiency. Our hypothesis is that intermittent oral iron supplementation is at least as effective as iron supplementation once daily and will give less adverse effects.
Objective of the study:
To compare the efficacy, side effects and therapy compliance of intermittent (three times a week) versus daily oral iron supplementation for anaemia in pregnancy attributed to iron deficiency.
Study design:
Single-centre, non-inferiority, open-label randomised controlled trial.
Study population:
Pregnant women of 18 years and older with iron deficiency anaemia.
Intervention:
One group will receive ferrous fumarate 200mg intermittent three times a week (for example on Monday, Wednesday and Friday) and one group will receive ferrous fumarate 200mg once daily.
Screening for anaemia during the pregnancy will be done according the local protocol in the first trimester and at a gestational age of 30 weeks. In women at risk for anaemia extra haemoglobin level will be measured at a gestational age of 20 weeks.
When a patient is eligible for the study she will be computer-randomised. Haemoglobin levels will be measured every 6 weeks after the start of the supplementation until the delivery. Side effects and therapy compliance will be evaluated with an interview.
Primary study parameters/outcome of the study:
The main endpoint of the study is the difference in haemoglobin level from baseline to 6 weeks as a continuous variable. A multivariate analysis will be performed with gestational age/trimester at start iron supplementation, the duration of the treatment, use of other supplements, vegetarian diet and the use of proton pump inhibitors or H2 receptor antagonists.
Secondary study parameters/outcome of the study:
The secondary endpoints are haemoglobin level at time of delivery, side effects, therapy compliance, term of delivery, birth weight, parenteral iron ante- or postpartum and blood transfusion postpartum.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intermittent
This group will receive ferrous fumarate 200mg intermittent three times a week on alternate days.
Ferrous fumarate
Ferrous fumarate 200mg oral
Daily
This group will receive ferrous fumarate 200mg once daily.
Ferrous fumarate
Ferrous fumarate 200mg oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ferrous fumarate
Ferrous fumarate 200mg oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Iron deficiency anaemia (defined as: Anaemia (haemoglobin lower than cut-off value) AND mean corpuscular volume (MCV) 70-85 fl OR ferritin \<30ug/L) OR mean corpuscular volume (MCV) \< 70fl / hemoglobinopathy is ruled out.
* Adequate mental health
* Good command of the Dutch language
* No participation in other research with medication
* Informed consent
Exclusion Criteria
* History of bariatric surgery, inflammatory bowel disease, coeliac disease or Helicobacter pylori infection (because of malabsorption of iron).
* Patients who received blood transfusion or parental iron supplementation during the 3 months prior to screening (because of the effect on the haemoglobin level).
* Patients with significant bleeding, blood donation or surgery during pregnancy (because of the effect on the haemoglobin level).
* Allergy for iron.
* Anaemia of other cause, such as a hemoglobinopathy.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
dr. J.M. Munster, gynaecologist, principal investigator
UNKNOWN
Martini Hospital Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maryse de Graaf
drs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Martini Hospital Groningen
Groningen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-005393-26
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
NL77578.000.21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.